|
See related Caelyx infusion conc information |
|
|
|
Manufacturer |
Johnson & Johnson |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Pegylated liposomal doxorubicin HCl |
|
Indications |
As monotherapy for patients w/ metastatic breast cancer, where there is an increased cardiac risk. Treatment of advanced ovarian cancer in women who have failed a 1st-line platinum-based chemotherapy regimen. In combination w/ bortezomib for the treatment of progressive multiple myeloma in patients who have received at least 1 prior therapy & who have already undergone or are unsuitable for bone marrow transplant. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts & extensive mucocutaneous or visceral disease. May be used as 1st-line systemic chemotherapy, or as 2nd-line chemotherapy in AIDS-related KS patients w/ disease that has progressed w/, or who are intolerant to, prior combination systemic chemotherapy comprising at least 2 agents eg a vinca alkaloid, bleomycin & standard doxorubicin (or other anthracyclines). |
|
Dosage |
Breast/ovarian cancer 50 mg/m2 IV infusion once every 4 wk. Multiple myeloma 30 mg/m2 on day 4 of the bortezomib 3-wk regimen as 1-hr infusion immediately after bortezomib infusion. AIDS-related KS 20 mg/m2 IV infusion over 30 min every 2-3 weeks. |
|
Contraindications |
Hypersensitivity. Pregnancy & lactation. Should not be used to treat AIDS-related KS that may be effectively treated w/ local therapy or systemic α-interferon. |
|
Special Precautions |
Cardiac risk, myelosuppression, diabetes, infusion-associated reactions. Renal or hepatic impairment. Childn <18 yr. |
|
Adverse Drug Reactions |
Fever, nausea, asthenia, alopecia, diarrhoea, infusion-associated acute reactions & stomatitis.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Caelyx infusion concentrate |
|
Caelyx 2 mg/1 mL x 1's |
 |
|
|
|
Manufacturer: |
Johnson & Johnson |
|
Distributor: |
Hong Kong: DKSH |
|
Marketer: |
Janssen
|
|
|
|
